NEOVASCULAR AGE RELATED MACULAR DEGENERATION
Clinical trials for NEOVASCULAR AGE RELATED MACULAR DEGENERATION explained in plain language.
Never miss a new study
Get alerted when new NEOVASCULAR AGE RELATED MACULAR DEGENERATION trials appear
Sign up with your email to follow new studies for NEOVASCULAR AGE RELATED MACULAR DEGENERATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gene therapy shot aims to tame leading cause of blindness
Disease control OngoingThis study tests a new gene therapy called LX102 for people with wet age-related macular degeneration (nAMD), a common cause of vision loss. About 50 adults aged 50 to 89 who have already responded to standard anti-VEGF injections will receive the treatment. The goal is to see if…
Matched conditions: NEOVASCULAR AGE RELATED MACULAR DEGENERATION
Phase: PHASE2 • Sponsor: Innostellar Biotherapeutics Co.,Ltd • Aim: Disease control
Last updated May 17, 2026 08:15 UTC
-
New eye drug shows promise in early trial for blinding disease
Disease control OngoingThis early-stage study tests an experimental drug called ASKG712, given as an eye injection, for people with wet age-related macular degeneration (a leading cause of vision loss). The main goal is to check safety and how the body handles the drug, with 56 participants receiving d…
Matched conditions: NEOVASCULAR AGE RELATED MACULAR DEGENERATION
Phase: PHASE1 • Sponsor: AskGene Pharma, Inc. • Aim: Disease control
Last updated May 17, 2026 08:02 UTC
-
Eye injection showdown: which drug needs fewer shots for wet AMD?
Disease control OngoingThis study compares two drugs, bevacizumab and aflibercept, given as eye injections to treat wet age-related macular degeneration (AMD). About 402 adults aged 50 and older with wet AMD will receive one of the two drugs for two years. The goal is to see which drug requires fewer i…
Matched conditions: NEOVASCULAR AGE RELATED MACULAR DEGENERATION
Phase: PHASE2 • Sponsor: Vastra Gotaland Region • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New syringe design tested for common eye disease treatment
Disease control OngoingThis study tests whether a pre-filled syringe is as safe as the standard vial when giving an eye injection for wet age-related macular degeneration, diabetic macular edema, or branch retinal vein occlusion. About 120 people will receive the drug ONS-5010 (bevacizumab) either from…
Matched conditions: NEOVASCULAR AGE RELATED MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: Outlook Therapeutics, Inc. • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
One-Time gene therapy could free wet AMD patients from lifelong eye injections
Disease control OngoingThis study tests a one-time gene therapy called RGX-314 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if a single treatment can control the disease and reduce the need for repeated eye injections. About 671 adults a…
Matched conditions: NEOVASCULAR AGE RELATED MACULAR DEGENERATION
Phase: PHASE2, PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
Higher-Dose eye injection studied for two common Vision-Threatening conditions
Disease control OngoingThis study tests a higher dose of the drug aflibercept given as an eye injection every 4 weeks in about 1,100 adults with wet age-related macular degeneration (AMD) or diabetic macular edema (DME). All participants have been treated before with similar drugs. The main goal is to …
Matched conditions: NEOVASCULAR AGE RELATED MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
Gene therapy for wet AMD: Long-Term safety check underway
Disease control OngoingThis study follows 23 people who received a single dose of ADVM-022 gene therapy for wet age-related macular degeneration (AMD) in an earlier trial. Researchers are monitoring long-term safety and how well the treatment controls vision loss and retinal swelling over time. The goa…
Matched conditions: NEOVASCULAR AGE RELATED MACULAR DEGENERATION
Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control
Last updated May 11, 2026 20:46 UTC
-
Massive eye study tracks Real-World drug performance in 6,000 patients
Knowledge-focused OngoingThis study is observing 6,000 adults already receiving Roche eye treatments for conditions like wet macular degeneration and diabetic eye swelling. It does not test new drugs or change standard care. Instead, it collects long-term data on vision changes, treatment patterns, and s…
Matched conditions: NEOVASCULAR AGE RELATED MACULAR DEGENERATION
Sponsor: Hoffmann-La Roche • Aim: Knowledge-focused
Last updated May 15, 2026 11:55 UTC